Abstract: Proposed are preparations, comprising special amides and menthol or menthol compounds or aromatic substances, characterized in that they have improved flavor and scent properties, and also that they allow the production of preparations, particularly emulsions with improved shelf life.

Abstract: Described herein are oral care compositions comprising a mixture of zinc oxide and trimethylglycine, in free or orally acceptable salt form. Methods of making and using the compositions are also provided.

Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release.

Abstract: Provided is a flavor modifying composition including a blend of a water soluble filler including plant fibers; and at least one sucrose substitute of natural source, wherein said flavor modifying composition includes at least 90% w/w of the filler, the amount being determined when said composition is in dry form; and said flavor modifying composition is water soluble. The flavor modifying composition is particularly effective in enhancing sweet taste and/or aroma of a product. Further provided are products including the flavor modifying composition.

Abstract: Provided is a substance inhibiting an odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone. An inhibitor of an odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone, comprising a substance inhibiting the response of an olfactory receptor OR5K1 as an active ingredient.

Abstract: The invention provides oral care compositions comprising a mixture of tetrabasic zinc halide and trimethylglycine, in free or orally acceptable salt form. Methods of making and using the compositions are also provided.

Abstract: An anti-bacterial mouthwash includes aqueous extracts of Salvia libanotica and Malva sylvestris plants, at least one essential oil, and an emulsifier. The essential oil can include at least one of eucalyptus oil and peppermint oil. The emulsifier can include polyoxyethylene sorbitan. The anti-bacterial mouthwash can be free from alcohol.

Abstract: The present invention is directed to novel aldehyde compounds and a method of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of the novel aldehyde compounds.

Abstract: An aqueous shear-thinning personal care composition comprises: (a) at least 3 wt % of a sulfonate compound of general formula (I): where R1 represents a C8-22 alkyl group alkyl group; R2 represents a C1-4 alkyl group; each of R3, R4 and R5 independently represents a hydrogen atom or a C1-4 alkyl group; and M+ represents a sodium or potassium cation; (b) at least 3 wt % of an amphoteric or zwitterionic surfactant; (c) at least 10 wt % of water; and (d) at least 0.5 wt % of an additional component in the form of particles or droplets suspended in the composition. The composition is stable in an aqueous environment and can be formulated with a wide range of additional components.

Abstract: The invention is associated with ingestible film coated solid dosage forms comprising natural honey in the coating applied to such forms. The natural honey of the film coated solid dosage form is of sufficient level to be perceived by the user while avoiding sticking to each other or the packaging with which they are in contact and, or storage.

Abstract: A composition with reduced bitterness containing polyquaternium-2, polyquaternium-17, and/or polyquaternium-18.

Abstract: Perfume-free malodor reducing compositions comprising a malodor binding polymer and a malodor counteractant are provided. In some embodiments, the composition comprises a malodor binding polymer and GLDA. Such compositions may be used to reduce malodor on inanimate surfaces or in the air.

Abstract: An oral care composition and methods for making and using same are provided. In at least one embodiment, the oral care composition can include ethylcellulose, a binder, a plasticizer, a fluoride compound, a solvent, and fumed silica. In another embodiment, the oral care composition can include ethylcellulose, hydrogenated rosin, and acetyl tributyl citrate.

Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.

Abstract: The invention provides compositions with low toxicity and high bioavailability for treating cancer or for inhibiting the development of cancer.

Abstract: Dosage forms provided with protective coatings in which a core comprising at least one acidic active ingredient is provided with at least one inner and one outer coating layer, where the outer layer comprises, as component A, a cationic polymer which is an emulsion polymer of N,N-diethylaminoethyl methacrylate and further monomers.

Abstract: Provided are compositions, e.g., oral and personal care products, comprising (i) a tetrabasic zinc-amino acid or trialkyl glycine-halide complex, and (ii) cysteine in free or in orally or cosmetically acceptable salt form, together with methods of making and using the same.

Abstract: An improved method for manufacture of chewing gums containing active ingredient(s) that preserves the efficacy of the active ingredient(s) by avoiding exposure to high heat and extreme cold during milling that can otherwise degrade the active's efficacy. A chewing gum base is used, along with one or more therapeutically-active ingredients, one or more sweeteners (alcohol-based and/or natural), and one or more flavorings and optional flavor modifiers. The method generally comprises heating the gum base in ovens to melt the gum base. Separately, the active ingredient(s), sweeteners and flavorings are combined in a mixer. The melted gum base is added to the mixer and cools to produce a particulate mixture. As mixing continues the mass cools to room temperature and forms granular pieces. The granular pieces are ground into a powder at room temperature, mixed at room temperature with tableting excipients, and tableted. Several variations on the foregoing are also described.

Abstract: A mixtures which contain (a) at least one phenylalkenal of formula (I) wherein R1 and R2 independently represent hydrogen, a methyl or phenyl group, R3 represents hydrogen, a phenyl group, alkenyl group or a linear or branched alkyl group with 1 to 5 carbon atoms, and the broken double lines independently represent a single bond or a double bond, and (b) at least one physiological cooling agent.

Abstract: Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation.